Key Points
- Director Luke Evnin sold 80,852 shares of Werewolf Therapeutics on May 27 at an average price of $0.48, totaling about $38,809. The sale was made under a pre-arranged Rule 10b5-1 trading plan.
- Evnin has made multiple recent insider sales across May, trimming his ownership by 10.59% after the May 27 transaction and selling hundreds of thousands of shares over the past several trading days.
- Werewolf Therapeutics stock remains under pressure, trading around $0.45 versus a 52-week high of $2.38, while the company recently posted a smaller-than-expected quarterly loss and analysts currently rate the stock a Hold on average.
Werewolf Therapeutics, Inc. (NASDAQ:HOWL - Get Free Report) Director Luke Evnin sold 27,698 shares of the firm's stock in a transaction that occurred on Thursday, May 28th. The stock was sold at an average price of $0.46, for a total transaction of $12,741.08. Following the sale, the director owned 655,135 shares of the company's stock, valued at $301,362.10. The trade was a 4.06% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Luke Evnin also recently made the following trade(s):
- On Friday, May 29th, Luke Evnin sold 32,556 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $14,650.20.
- On Wednesday, May 27th, Luke Evnin sold 80,852 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.48, for a total transaction of $38,808.96.
- On Tuesday, May 26th, Luke Evnin sold 67,950 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.47, for a total transaction of $31,936.50.
- On Friday, May 22nd, Luke Evnin sold 87,425 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $39,341.25.
- On Thursday, May 21st, Luke Evnin sold 36,387 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.42, for a total transaction of $15,282.54.
- On Wednesday, May 20th, Luke Evnin sold 85,895 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.43, for a total transaction of $36,934.85.
- On Tuesday, May 19th, Luke Evnin sold 62,970 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.45, for a total transaction of $28,336.50.
- On Monday, May 18th, Luke Evnin sold 22,184 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.50, for a total transaction of $11,092.00.
- On Tuesday, May 12th, Luke Evnin sold 67,885 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.64, for a total transaction of $43,446.40.
- On Monday, May 11th, Luke Evnin sold 33,948 shares of Werewolf Therapeutics stock. The stock was sold at an average price of $0.67, for a total transaction of $22,745.16.
Werewolf Therapeutics Stock Performance
Shares of NASDAQ:HOWL opened at $0.45 on Friday. The stock has a market capitalization of $21.87 million, a price-to-earnings ratio of -0.36 and a beta of 0.41. Werewolf Therapeutics, Inc. has a 1-year low of $0.40 and a 1-year high of $2.38. The company has a 50 day moving average price of $0.74 and a 200 day moving average price of $0.75.
Werewolf Therapeutics (NASDAQ:HOWL - Get Free Report) last issued its earnings results on Thursday, May 7th. The company reported ($0.28) earnings per share for the quarter, topping analysts' consensus estimates of ($0.32) by $0.04. On average, sell-side analysts expect that Werewolf Therapeutics, Inc. will post -1.29 EPS for the current fiscal year.
Analyst Ratings Changes
A number of research firms recently commented on HOWL. Wall Street Zen lowered shares of Werewolf Therapeutics from a "hold" rating to a "sell" rating in a research note on Saturday, May 9th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Werewolf Therapeutics in a research note on Monday, April 20th. Two investment analysts have rated the stock with a Buy rating, four have assigned a Hold rating and one has assigned a Sell rating to the stock. According to data from MarketBeat, Werewolf Therapeutics presently has a consensus rating of "Hold" and a consensus target price of $3.75.
Check Out Our Latest Research Report on Werewolf Therapeutics
Hedge Funds Weigh In On Werewolf Therapeutics
Hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Qube Research & Technologies Ltd acquired a new position in Werewolf Therapeutics in the 2nd quarter worth approximately $48,000. Regal Investment Advisors LLC boosted its stake in Werewolf Therapeutics by 93.3% in the 4th quarter. Regal Investment Advisors LLC now owns 52,593 shares of the company's stock worth $33,000 after purchasing an additional 25,389 shares during the period. Vontobel Holding Ltd. boosted its stake in Werewolf Therapeutics by 66.7% in the 4th quarter. Vontobel Holding Ltd. now owns 60,003 shares of the company's stock worth $38,000 after purchasing an additional 24,003 shares during the period. AQR Capital Management LLC acquired a new position in Werewolf Therapeutics in the 1st quarter worth approximately $79,000. Finally, Susquehanna International Group LLP boosted its stake in Werewolf Therapeutics by 16.9% in the 3rd quarter. Susquehanna International Group LLP now owns 93,041 shares of the company's stock worth $183,000 after purchasing an additional 13,439 shares during the period. Institutional investors and hedge funds own 64.84% of the company's stock.
About Werewolf Therapeutics
(
Get Free Report)
Werewolf Therapeutics, Inc (NASDAQ: HOWL) is a clinical-stage biotechnology company focused on the development of next-generation immunotherapies for the treatment of solid tumors. The company's proprietary Conditional Activation Platform is designed to keep therapeutic molecules inert in healthy tissues and selectively activate them within the tumor microenvironment, aiming to enhance anti-tumor efficacy while minimizing systemic toxicity.
Leveraging this platform, Werewolf Therapeutics is advancing multiple programs that include conditionally activated cytokine candidates and bi-specific antibody constructs.
Recommended Stories
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
